GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Feng Chi Biotech Corp (ROCO:6744) » Definitions » Net Income From Continuing Operations

Feng Chi Biotech (ROCO:6744) Net Income From Continuing Operations : NT$27.3 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Feng Chi Biotech Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Feng Chi Biotech's net income from continuing operations for the six months ended in Dec. 2023 was NT$10.7 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was NT$27.3 Mil.

Feng Chi Biotech Net Income From Continuing Operations Historical Data

The historical data trend for Feng Chi Biotech's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feng Chi Biotech Net Income From Continuing Operations Chart

Feng Chi Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial 21.69 29.83 28.06 30.42 27.30

Feng Chi Biotech Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.41 17.77 12.65 16.65 10.65

Feng Chi Biotech Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$27.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Feng Chi Biotech (ROCO:6744) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Feng Chi Biotech Corp (ROCO:6744) » Definitions » Net Income From Continuing Operations
Comparable Companies
ROCO:4197 ROCO:6848 ROCO:6864 ROCO:6662 ROCO:4131 ROCO:3118 ROCO:6917 ROCO:6814 ROCO:6549 ROCO:6808 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100
Website
http://www.fcbiotech.com.tw
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.

Feng Chi Biotech (ROCO:6744) Headlines

No Headlines